On average, 1 in 5 needle biopsies fail to collect a sufficient sample to make a diagnosis. Large medical facilities have been forced to staff pathologists during routine biopsy procedures – leaving small and more rural facilities unable to implement this practice, known as Rapid Onsite Evaluation (ROSE). In response to these issues, we have developed the Bioptic™ platform to automate ROSE and enable hospitals of every size to mitigate both the expensive failure rate and time-consuming procedure.
Prior to diagnosis, pathologists spend about 1-hour assessing the quality of all tissue samples collected using traditional microscopy methods; therefore reviewing less than 1% of each sample for its features. Bioptic™ vastly reduces the time clinicians spend assessing a slide by providing the key tissue information and sample metrics, all calculated from a whole slide image.
Bioptic™ works into an already established reimbursement structure, enabling hospitals to generate more revenue while improving the care they provide; we’re proud proponents of this profit-sharing model. Every sample assessed by the Bioptic™ unit is reimbursed by insurance providers – they know well the financial and clinical value of biopsy quality assessment. Our pricing model is lower than current reimbursement values, allowing hospitals of any size to verify that every patient will get their diagnosis after the first biopsy and generate revenue doing so.